American Society of Hirudotherapy

Dupuytren's Contracture (Early Stage)

Investigational use in Dupuytren's disease; evidence limited to one uncontrolled Russian-language report in patients with contracture.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 12, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for Dupuytren's contracture. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
What evidence exists?
Tier C (investigational). No controlled study of leech therapy for Dupuytren contracture was identified; the only clinical report found is an uncontrolled Russian-language account from 1998 that does not state how many patients were treated. Evidence-based options for established contracture include needle aponeurotomy (percutaneous needling), intralesional collagenase clostridium histolyticum injection (FDA-approved as Xiaflex for adults with palpable cord and contracture), and limited fasciectomy (gold standard for severe disease). Leech therapy does NOT lyse mature collagen cords.
Main risks
  • Bleeding from bite sites on the palm for 6 to 24 hours after detachment
  • Bruising and tenderness over the palm for 5 to 10 days
  • Damage to the digital neurovascular bundle if placement is improperly over the flexor tendon
  • Local skin infection or, rarely, Aeromonas infection
  • Allergic reaction to leech saliva (uncommon)
  • Cosmetic visible scars at bite sites on the palm
  • Delay of definitive collagenase injection or fasciectomy with progressive contracture
  • Inability to address established cord-related contracture (leeches cannot lyse mature collagen)
Who should not consider this
  • Patients with established contracture greater than 30 degrees (MP or PIP) — surgical or collagenase indication
  • Patients with a positive Hueston tabletop test (cannot place palm flat)
  • Patients with active palm infection
  • Patients on anticoagulants, with hemophilia, or with anemia
  • Patients who have not been evaluated by a hand surgeon
  • Patients with rapid progression or aggressive Dupuytren's diathesis
What to ask your clinician
  • What is my contracture in degrees (MP and PIP), and what is my Hueston tabletop test result?
  • Have I been evaluated by a hand surgeon, and am I a candidate for collagenase injection (Xiaflex)?
  • Am I a candidate for needle aponeurotomy or limited fasciectomy?
  • What is the natural history of my disease (Dupuytren's diathesis: bilateral, young onset, family history, ectopic disease)?
  • What evidence supports leech therapy for Dupuytren's — and only for early nodules versus established cords?
  • Where exactly will leeches be placed — over nodules and away from the flexor tendon course?
  • What is the practitioner's experience and Aeromonas-prevention plan?
When to seek urgent care
  • Sudden severe palm pain, swelling, or inability to flex / extend the finger (possible flexor tenosynovitis — surgical emergency)
  • Spreading redness, warmth, pus, or red streaks on the palm (cellulitis)
  • New numbness, coldness, or pallor of the finger
  • Bleeding from a bite site lasting more than 24 to 48 hours
  • Fever above 38.0 C / 100.4 F or chills
  • Hives, throat tightness, or breathing difficulty

What this does NOT mean

  • This is not FDA-cleared for Dupuytren's contracture.
  • A single uncontrolled report does NOT establish efficacy for early nodules or for established contracture.
  • Mechanism rationale (early antifibrotic effects) does NOT lyse mature collagen cords.
  • Leech therapy is not a substitute for collagenase injection (Xiaflex), needle aponeurotomy, or fasciectomy when indicated.
  • Established contracture causing functional limitation requires hand-surgical evaluation, NOT complementary therapy.

Clinical Profile

Category
Musculoskeletal
ICD-10
M72.0
Safety tier
Low

Evidence Summary

No controlled clinical trial of leech therapy for Dupuytren's disease was identified in PubMed, Europe PMC, Crossref or Russian- and German-language searches. The only clinical report found is an uncontrolled Russian account (Serkov 1998, summarized in Baskova and Isakhanyan 2004; the number of patients is not stated) in which treatment was followed by softening of fibrous scars and better finger joint motion in patients with contracture. That report has not been independently confirmed and cannot show that leeches soften palmar nodules or alter disease course, and no controlled evidence shows an effect on established collagen cords. Any proposed antifibrotic mechanism is speculative and unproven. For established contracture causing functional limitation, evidence-based treatment (collagenase clostridium histolyticum injection, needle aponeurotomy, or limited fasciectomy) is required. ASH position: any use of leech therapy for Dupuytren's disease is investigational and supported only by one uncontrolled report.

What the books describe

Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.

  • Baskova and Isakhanyan include Dupuytren’s syndrome in a list, compiled by them with reference to published data, of conditions for which leech treatment is recommended[B1].
  • They describe this syndrome as a gradually developing flexion contracture of one or more fingers, mainly on the ulnar side, citing Serkov (1998); it is not entirely clear from the text whether this reference applies only to the definition of the disease or also to the description of treatment that follows[B1].
  • As they retell it, treatment with leeches helped to soften fibrous scars and increase the range of motion in the interphalangeal joints[B1].
  • How many patients were observed, at what stage of the disease, whether there was a comparison group and how long the result was followed is not stated in the text[B1].
  • Michalsen et al. do not write about Dupuytren’s contracture[B3].
  • Among the contraindications, Baskova and Isakhanyan name, for example, hemophilia, anemias and concurrent use of anticoagulants; Michalsen et al. (chapter 8, Flecken and Michalsen) likewise regard taking anticoagulants as an absolute contraindication, and do not regard aspirin and clopidogrel as contraindications in themselves — in that case, in their words, fewer leeches are applied at the first leech treatment session[B1][B3].

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Established contracture >30 degrees (surgical referral)
  • Active palmar infection

Related Conditions

References

  • [B1]

    Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]

    Москва: Монолит(2004)https://search.rsl.ru/ru/record/01007959553

    Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.

  • [B3]

    Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy

    Stuttgart — New York: Thieme(2007)https://books.google.com/books?vid=ISBN9781588905635

    ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.

The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.